| Autor: |
David Wasilewski, Jan Bukatz, Ricarda Peukert, Zoe Shaked, Paul Poeser, Anna-Gila Karbe, null Anna-Trelinska-Finger, Claudius Jelgersma, Anton Früh, Matthias Raspe, Helena Radbruch, David Capper, Max Schlaak, Peter Thuss-Patience, Philip Bischoff, David Horst, Marcel Krenzke, Ran Xu, Felix Ehret, David Kaul, Martin Misch, Lars Bullinger, Nikolaj Frost, Peter Vajkoczy, Julia Onken |
| Rok vydání: |
2023 |
| Popis: |
BackgroundPatients with brain metastases that undergo brain metastasis resection regularly receive perioperative dexamethasone. We sought to evaluate whether perioperative dexamethasone in brain metastases is linked to survival.MethodsRetrospective data on perioperative dexamethasone dosage in resected brain metastasis patients at three hospital sites of the Charité from 2010-2022 were collected. Cut-off values for cumulative perioperative dexamethasone dose as a continuous predictor variable for survival were determined using maximally selected rank statistics. Patients were dichotomized based on determined cut-offs of cumulative dexamethasone (pre-operative: < 40 mg vs ≥40 mg; post-operative: < 180 mg vs ≥ 180 mg) and pre- and postoperative: < 281 mg vs ≥ 281 mg). Medical records included baseline demographic, radiological, histopathological and treatment-related characteristics. Based on cut-off values for dexamethasone downstream statistical analyses included Kaplan-Meier, Cox proportional hazards regression for overall survival with adjustment for potential confounders including age, gender, Karnofsky performance status and presence of extracranial metastasis via propensity score matching.Results539 patients were included. Median follow-up time was 58,97 months. After adjusting for age, gender, Karnofsky performance status and presence of extracranial metastasis patients with higher cumulative perioperative dexamethasone (≥281 mg) showed shorter survival (HR: 1.47 (1.20-1.80, pConclusionCumulative perioperative dexamethasone is associated with decreased survival in the context of brain metastasis resection. Strict dosage, down taper or methods reducing corticosteroid dependency should be regularly evaluated in clinical practice in patients with brain metastases. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
